(4R^*,6R^*)-4-hydroxy-6-n-propyl-1-oxacyclohexan-2-one | 114431-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (4R^*,6R^*)-4-hydroxy-6-n-propyl-1-oxacyclohexan-2-one
• 英文别名: (+/-)-trans-4-hydroxy-6-propyl-1-oxa-cyclohexan-2-one；(4R,6R)-4-hydroxy-6-propyloxan-2-one
• CAS: 114431-79-7
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: TWSUWPLPZNCARG-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl (3R,5R)-3,5-dihydroxyoctanoate 生成 (4R^*,6R^*)-4-hydroxy-6-n-propyl-1-oxacyclohexan-2-one
  参考文献：
  名称：

  KATHAWALA, F. G.;PRAGER, B.;PRASAD, K.;REPIC, O.;SHAPIRO, M. J.;STABIER, +, HELV. CHIM. ACTA, 1986, 69, N 4, 803-815

  摘要：

  DOI：

文献信息

• Stereochemistry of conjugate addition to 4- and 5-substituted α,β-unsaturated δ-lactones
  作者：Ian Fleming、N. Laxma Reddy、Ken Takaki、Anne C. Ware

  DOI：10.1039/c39870001472

  日期：——

  Conjugate addition, especially of the phenyldimethylsilylcuprate reagent, to 4- and 5-substituted α,β-unsaturated δ-lactones [(5) and (18)] is highly selective for the formation of the trans-products [(6), (7), (9), (10), and (19)], the silicon-containing products having 1H n.m.r. coupling constants indicative of distortions from the chair conformation; the silyl group can be converted into a hydroxy

  共轭加成，特别是苯基二甲基甲硅烷基铜酸酯试剂向4和5取代的α，β-不饱和δ-内酯[（5）和（18）]的加成对形成反式产物[（6），（图7），（9），（10）和（19）]，具有1 H nmr耦合常数的含硅产物表示椅子构象的变形；甲硅烷基可以转化为羟基以得到内酯（8）和（20）。
• A one-pot conversion of the phenyldimethylsilyl group into a hydroxyl group
  作者：Ian Fleming、Philip E.J. Sanderson

  DOI：10.1016/s0040-4039(00)95587-4

  日期：——

  A phenyldimethylsilyl group attached to carbon can be converted into a hydroxyl group using either bromine or mercuric ion in an acetic acid solution of peracetic acid.

  可以使用溴或汞离子在过氧乙酸的乙酸溶液中将与碳相连的苯基二甲基甲硅烷基转化为羟基。
• Substituted pyrrole derivatives and their use as HMG-CO inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2319843A1

  公开（公告）日：2011-05-11

  The present invention relates to substituted pyrrole derivatives, which can be used as 2-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

  本发明涉及可用作 2-羟基-3-甲基戊二酰辅酶 A（HMG-CoA）还原酶抑制剂的取代吡咯衍生物。本文公开的化合物可作为降低胆固醇的药物，并可用于治疗胆固醇相关疾病及相关症状。本文提供了制备所公开化合物的工艺，以及含有所公开化合物的药物组合物和治疗胆固醇相关疾病及相关症状的方法。
• Molander, Gary A.; Etter, Jeffrey B.; Harring, Lori S., Journal of the American Chemical Society, 1991, vol. 113, # 21, p. 8036 - 8045
  作者：Molander, Gary A.、Etter, Jeffrey B.、Harring, Lori S.、Thorel, Pierre-Jean

  DOI：——

  日期：——
• Lanthanides in organic synthesis. 8. 1.3-Asymmetric induction in intramolecular Reformatskii-type reactions promoted by samarium diiodide
  作者：Gary A. Molander、Jeffrey B. Etter

  DOI：10.1021/ja00255a076

  日期：1987.10